Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.98−0.19 (-5.99%)
Close on Nov 19, 2026Market cap $110.80MP/E –Yield –
Armata Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Armata Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$25.79M. For fiscal 2025 it was -$26.31M. The highest annual figure on record is -$6.39M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.31M | – |
| FY2024 | Dec 31, 2024 | -$39.43M | – |
| FY2023 | Dec 31, 2023 | -$55.57M | – |
| FY2022 | Dec 31, 2022 | -$34.69M | – |
| FY2021 | Dec 31, 2021 | -$24.88M | – |
| FY2020 | Dec 31, 2020 | -$19.09M | – |
| FY2019 | Dec 31, 2019 | -$15.81M | – |
| FY2018 | Dec 31, 2018 | -$11.50M | – |
| FY2017 | Dec 31, 2017 | -$9.25M | – |
| FY2016 | Dec 31, 2016 | -$10.89M | – |
| FY2015 | Dec 31, 2015 | -$9.99M | – |
| FY2014 | Dec 31, 2014 | -$13.77M | – |
| FY2013 | Dec 31, 2013 | -$6.39M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.85M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.73M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.85M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.28M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.03M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.63M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.28M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.55M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.67M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.96M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.75M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.95M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.60M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.18M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.39M | – |
| Q3 FY2017 | Sep 30, 2017 | -$626.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.51M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.16M | – |
See a number that looks wrong?